

Technology/ Title	BPR5K230/ An AXL and MERTK Dual Kinase Inhibitor- Novel anticancer and immunomodulatory agent		
Subtitle			
Technology Type	<input type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics	
	<input type="checkbox"/> Pharmaceutical	<input checked="" type="checkbox"/> Others: <u>Oncology/Cancer Immunotherapy</u>	
Contact Person	Name: Cindy Hsieh		Title: Manager
	Telephone(work): +886-37246166-33209		Mobile:
	Email: wenchuan@nhri.edu.tw		
Link	https://ibpr.nhri.edu.tw/zhtw/wp-content/uploads/2023/06/NCR-of-AXL-MERTK-JY-edit-as-of-5-31-2023.pdf		
Technology Description	<p>Introduction</p> <p>AXL and MERTK are members of TAM (TYRO3, AXL and MERTK) receptor tyrosine kinases. Both AXL and MERTK play important roles in tumor progression, metastasis, drug resistance and immune evasion. Thus, dual AXL and MERTK inhibition in the tumor and tumor immune microenvironment would enhance anti-tumor efficacy and boost anti-tumor immune responses.</p> <p>Key Futures</p> <ul style="list-style-type: none"> • BPR5K230 is a potent, orally bioavailable small molecule AXL and MERTK with anti-tumor and immunomodulatory activities • BPR5K230 demonstrates single agent anti-tumor effect, prevent lung metastasis and prolongs median survival days in combination with immune checkpoint inhibitors in multiple preclinical murine tumor models • The anti-tumor effect of BPR5K230 was more efficacious than the clinical stage agent Ono-7475 In multiple preclinical models evaluated • BPR5K230 is most suitable for patients who fail current therapies and whose tumors and immune cells overexpress AXL and MERTK <p>Status</p> <ul style="list-style-type: none"> • Candidate-like Optimized lead compound identified <p>Market Positioning</p> <ul style="list-style-type: none"> • Novel AXL and MERTK dual kinase inhibitors can be positioned in kinase inhibitors markets, targeted cancer therapy market and immuno-oncology market. 		

Intellectual Property	US patent application filed in August, 2023 including 174 examples of a series of pyrimidine-like heterocyclic derivatives as potent AXL/MERTK dual kinase inhibitors
Key Publications	NA
Business Opportunity	Technology transfer, co-development, sponsored research

